Research
Molecular
The post-ACCORD era represents a significant shift in the landscape of cardiovascular outcomes trials (CVOTs) in type 2 diabetes mellitus (T2DM), emphasizing the safety of glucose-lowering agents.
Practitioners should prioritize the safety profiles of glucose-lowering agents in T2DM management.
StrongSupportsmedium confidence
The post-ACCORD era is representative of a significant shift in the landscape of CVOTs in T2DM, with an emphasis on safety of glucose-lowering agents.
Why this rating
The review of multiple CVOTs indicates a high level of evidence.
Source
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Karan Kapoor et al. · Cardiology · 2016
reviewCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →